-
Mashup Score: 2Comment on: European Heart Journal Global Spotlight on EMA Evaluation of Mavacamten - 1 month(s) ago
John A Spertus, MD MPH; Comment on: European Heart Journal Global Spotlight on EMA Evaluation of Mavacamten, European Heart Journal Open, , oeae013, https://doi
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0
Ted Abraham, MD, explained why HCM has entered the limelight at recent cardiology conferences, including ASE 2023.
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Video of Ted Abraham, MD, UCSF, explaining why HCM has come into the limelight at cardiology conferences, most notably at #ASE2023. #Cardiotwitter #HCM @ASE360 #echofirst #Mavacamten https://t.co/fECPSKTmAJ
-
-
Mashup Score: 0FDA approves updated label for mavacamten - 10 month(s) ago
Bristol Myers Squibb announced that the FDA has approved updated labeling for mavacamten to reflect positive data from the VALOR-HCM trial.Mavacamten (Camzyos), a cardiac myosin inhibitor, in April 2022 became the first drug approved by the FDA to treat NYHA class II or III obstructive hypertrophic cardiomyopathy (HCM).
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: Bristol Myers Squibb announced that the FDA has approved updated labeling for #mavacamten to reflect positive data from the VALOR-HCM trial @US_FDA @#cardiotwitter https://t.co/kLneaNPHDk
-
-
Mashup Score: 1FDA approves updated label for mavacamten - 10 month(s) ago
Bristol Myers Squibb announced that the FDA has approved updated labeling for mavacamten to reflect positive data from the VALOR-HCM trial.Mavacamten (Camzyos), a cardiac myosin inhibitor, in April 2022 became the first drug approved by the FDA to treat NYHA class II or III obstructive hypertrophic cardiomyopathy (HCM).
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: Bristol Myers Squibb announced that the FDA has approved updated labeling for #mavacamten to reflect positive data from the VALOR-HCM trial @US_FDA @#cardiotwitter https://t.co/kLneaNPHDk
-
-
Mashup Score: 1FDA approves updated label for mavacamten - 10 month(s) ago
Bristol Myers Squibb announced that the FDA has approved updated labeling for mavacamten to reflect positive data from the VALOR-HCM trial.Mavacamten (Camzyos), a cardiac myosin inhibitor, in April 2022 became the first drug approved by the FDA to treat NYHA class II or III obstructive hypertrophic cardiomyopathy (HCM).
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Bristol Myers Squibb announced that the FDA has approved updated labeling for #mavacamten to reflect positive data from the VALOR-HCM trial @US_FDA @#cardiotwitter https://t.co/kLneaNPHDk
-
-
Mashup Score: 0
If approved, CAMZYOS would be the first cardiac myosin inhibitor in Europe that specifically targets the source of obstructive HCM Recommendation based on positive Phase 3 EXPLORER-HCM and VALOR-HCM trials demonstrating benefit in patients receiving CAMZYOS versus placebo Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the…
Source: news.bms.comCategories: Cardiologists, Latest HeadlinesTweet-
Positive CHMP opinion on #mavacamten So far mavacamten is approved in the US, Canada, Brazil, Australia, & Switzerland https://t.co/XSuGZTiNBL #CardioTwitter
-
-
Mashup Score: 1Mavacamten improves functional status beyond peak O2 in patients with obstructive HCM - 1 year(s) ago
Mavacamten improved a range of cardiopulmonary exercise testing parameters beyond peak oxygen uptake in patients with obstructive hypertrophic cardiomyopathy in the EXPLORER-HCM randomized trial, researchers reported.A secondary analysis of the EXPLORER-HCM trial of mavacamten (Camzyos, Bristol Myers Squibb) — a first-in-class cardiac myosin inhibitor — compared with placebo for the
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#Mavacamten improved a range of cardiopulmonary exercise testing parameters beyond peak oxygen uptake in patients with obstructive HCM in the EXPLORER-HCM randomized trial @JAMACardio @StanfordMed #cardiotwitter https://t.co/PiCRpN4Pes
-
-
Mashup Score: 0The Amyloidosis Forum | November 18, 2022 | Afternoon Sessions - 1 year(s) ago
Recording of the Afternoon Sessions from the Amyloidosis Forum: Potential Pathways for Development of Imaging Endpoints for Clinical Trials in AL and ATTR Am…
Source: YouTubeCategories: Cardiologists, Latest HeadlinesTweet-
Recordings from @Amyloidosis_ARC #Amyloidosisforum @US_FDA imaging endpoints meeting are posted now I discussed #HCM & #mavacamten RCTs as a case study for #ATTR #amyloidosis-watch here https://t.co/PqNWVyfXws https://t.co/wR76V0apfg #CardioTwitter #echofirst #whycmr #cvnuc
-
-
Mashup Score: 5Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy - 2 year(s) ago
Septal reduction therapy (SRT), surgical myectomy or alcohol ablation, is recommended for obstructive hypertrophic cardiomyopathy (oHCM) patients with…
Source: www.sciencedirect.comCategories: Expert Picks, Latest HeadlinesTweet-
In #HOCM patients with intractable symptoms, #mavacamten significantly reduced the fraction of patients meeting guideline criteria for Septal Reducation Therapy after 16 weeks. https://t.co/gY9DuP1v7r
-
-
Mashup Score: 0
Cardiology Today | Hypertrophic cardiomyopathy is the most common monogenic CV disorder, yet perhaps the most frequently misunderstood, and often goes undiagnosed in clinical practice.Patients with hypertrophic cardiomyopathy (HCM) have a wide spectrum of symptom presentation. Many people are asymptomatic; others experience severe HF, syncope and risk for sudden cardiac death due to ventricular…
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
“[HCM treatment] has always been a bit unsatisfying,” Kittleson said. “With #mavacamten ... You are going down to a molecular level to figure out the problem and address it.” -- @MKIttlesonMD https://t.co/Luf8rjoXaY #cardiotwitter #cardiology @CedarsSinai @bmsnews
-
Comment on: European Heart Journal Global Spotlight on EMA Evaluation of #Mavacamten https://t.co/1pfX0LgoPr